Eli Lilly (LLY)
(Delayed Data from NYSE)
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $891.00 -0.07 (-0.01%) 8:16 AM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $891.00 -0.07 (-0.01%) 8:16 AM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
by Zacks Equity Research
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Wells Fargo (WFC) and SAP SE (SAP).
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
by Kinjel Shah
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
by Zacks Equity Research
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU
by Zacks Equity Research
J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Nektar's Pain Drug Gets Adverse Advisory Committee Decision
by Zacks Equity Research
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
by Zacks Equity Research
Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.
Glaxo Files Marketing Application for Fostemsavir in Europe
by Zacks Equity Research
Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Company News for Jan 13, 2020
by Zacks Equity Research
Companies In The News Are: SNX, KBH, WDFC, LLY.
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate
by Zacks Equity Research
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $138, marking a +1.53% move from the previous day.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
by Zacks Equity Research
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company
by Zacks Equity Research
Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
by Kinjel Shah
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA
by Zacks Equity Research
AstraZeneca (AZN) gets the FDA's priority review status for its sNDA seeking label expansion of Farxiga for patients with heart failure with reduced ejection fraction.
3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
by Zacks Equity Research
Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.
Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
by Zacks Equity Research
Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.
Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor
by Zacks Equity Research
Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor